Sunnyvale, CA., February 18, 2015 -- Cardiva Medical, Inc. announced today that John Russell has been appointed President, Chief Executive Officer and member of the Cardiva Board of Directors. Mr. Russell succeeds Charles Maroney, who has served as CEO since June, 2010 and who will remain in his role as member of the Cardiva Board of Directors.
“As Cardiva prepares to enter the next phase of sales growth, we sought a leader who had direct commercial and market development experience, who could help the Company achieve its sales and profitability goals,” said Maroney. “John is an outstanding choice to lead the Company into this next phase of growth.”
John has over 30 years of experience in the medical device field including sales, marketing, business development and R&D. He was most recently CEO of Corventis, a venture capital financed medical device company that was acquired by Medtronic in 2014. During John’s tenure, Corventis commercialized a wearable, wireless patch system for monitoring cardiac patients in the US and 25 countries. Immediately prior to Corventis John was head of US Sales for the Cardiac Rhythm Management division of Boston Scientific, responsible for 1,300 employees and over $1.5 billion in revenue.
Earlier in his career John held positions as general manager, sales representative, regional sales manager, and sales director, as well as manager of market planning and director of new product planning at Guidant’s Cardiac Rhythm Management division. John holds a BS in mechanical engineering from Duke University and an MBA from the University of North Carolina, Chapel Hill.
Mr. Russell said, “Cardiva has an excellent opportunity to transform the vascular closure market and make a real difference for the millions of patients undergoing cardiac and peripheral vascular procedures. I am excited to join the team as it expands commercialization of VASCADE.”
Cardiva Medical, Inc. is a medical device company that’s focused on developing and commercializing innovative vascular closure technology designed to help the body heal itself following catheterization. The Company’s products include VASCADE, a next generation extravascular closure system and Catalyst II and Catalyst III that are designed to aid manual compression. VASCADE was approved by the FDA in 2013 and approved for CE marking in 2012. Catalyst II and Catalyst III were cleared for marketing by the FDA in 2007 and 2009, respectively. For more information, go to http://www.cardivamedical.com/
VASCADE® and Cardiva Catalyst® are registered trademarks of Cardiva Medical, Inc.
Chief Financial Officer
Cardiva Medical, Inc.